Effect of Helicobacter pylori infection and eradication therapy on gastric microbiota

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900024893

Enrollment

Unknown

Registered

2019-08-02

Start date

2019-09-02

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Group1-1:No

Group1-2-1:quadruple therapy combined with probiotics

Group1-2-2:quadruple therapy (esomeprazole, bismuth potassium citrate, amoxicillin, clarithromycin)

Group1-2-3:Probiotics (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live)

Group2-1:No

Group2-2-1:quadruple therapy combined with probiotics

Group2-2-2:quadruple therapy (esomeprazole, bismuth potassium citrate, amoxicillin, clarithromycin)

Group2-2-3:Probiotics (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live)

Eligibility

Sex/Gender

All

Age

18 Years to 30 Years

Inclusion criteria

Inclusion criteria: 1. Male or female aged 18 to 30 years old; 2. Asymptomatic volunteers,or patients who come to Peking University third hospital due to epigastric discomfort; 3. Volunteers or patients who are mentally clear and with good general situation; 4. Have regular work and eating habits; 5. No systemic diseases such as respiratory, circulatory, urinary, blood and endocrine diseases; 6. No infection, trauma or tumor; 7. Subjects who are capable of understanding the characteristics of this clinical trial and have full capacity for civil acts, agree to participate in this study and sign the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women or those with pregnancy needs in next six months; 2. Previous history of Helicobacter pylori eradication, digestive tract diseases and surgery; 3. Taking NSAIDs, antibiotics, mucosal protective agent, immunosuppressants, probiotics and acid-inhibiting drugs within one month; 4. Long-term smoking or drinking patients; 5. Endoscopic findings of bile reflux, ulcers and polyps; 6. Histopathological findings of atrophy, intestinal metaplasia, dysplasia, and tumor; 7. People who have participated in other clinical trials in the past 3 months.

Design outcomes

Primary

Measure	Time frame
gastric microbiota structure;fecal microbiota structure;	—

Secondary

Measure	Time frame
Gastric function indicator;HP elimination rate;	—

Countries

China

Contacts

Public ContactLiya ZHOU

Peking University Third Hospital

zhoumed@126.com+86 15611908239

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026